The present invention provides a method for purifying an organic compound, by which an organic compound having a reduced lead content is obtained from an organic compound that contains a lead component as an impurity. In this method for purifying an organic compound, the organic compound that contains a lead component is irradiated with ultraviolet light, and the lead component is subsequently removed from the organic compound. The present invention also provides a method for producing an organic compound, said method comprising purification of the organic compound by means of the above-described method for purifying an organic compound.

The present invention provides a method for purifying an organic compound, by which an organic compound having a reduced lead content is obtained from an organic compound that contains a lead component as an impurity. In this method for purifying an organic compound, the organic compound that contains a lead component is irradiated with ultraviolet light, and the lead component is subsequently removed from the organic compound. The present invention also provides a method for producing an organic compound, said method comprising purification of the organic compound by means of the above-described method for purifying an organic compound.

The present invention relates to oxopiperazines that mimic helix αB of the C-terminal transactivation domain of HIF1α. Also disclosed are pharmaceutical compositions containing these oxopiperazines and methods of using these oxopiperazines (e.g., to reduce gene transcription, treat or prevent disorders mediated by interaction of HIF1α with CREB-binding protein and/or p300, reduce or prevent angiogenesis in a tissue, induce apoptosis, and decrease cell survival and/or proliferation).

The present invention relates to oxopiperazines that mimic helix αB of the C-terminal transactivation domain of HIF1α. Also disclosed are pharmaceutical compositions containing these oxopiperazines and methods of using these oxopiperazines (e.g., to reduce gene transcription, treat or prevent disorders mediated by interaction of HIF1α with CREB-binding protein and/or p300, reduce or prevent angiogenesis in a tissue, induce apoptosis, and decrease cell survival and/or proliferation).

The present invention relates to oxopiperazines that mimic helix αB of the C-terminal transactivation domain of HIF1α. Also disclosed are pharmaceutical compositions containing these oxopiperazines and methods of using these oxopiperazines (e.g., to reduce gene transcription, treat or prevent disorders mediated by interaction of HIF1α with CREB-binding protein and/or p300, reduce or prevent angiogenesis in a tissue, induce apoptosis, and decrease cell survival and/or proliferation).

A product 1,3-butylene glycol, in which 2,4-dinitrophenylhydrazine derivatives of 2-(hydroxyethyl)-2,6-dimethyl-1,3-dioxane have a weight proportion of 90 ppm or less, as calculated from a sum of absorbance of peaks thereof in an HPLC analysis under specific conditions after specific sample preparation.

A product 1,3-butylene glycol, in which 2,4-dinitrophenylhydrazine derivatives of 2-(hydroxyethyl)-2,6-dimethyl-1,3-dioxane have a weight proportion of 90 ppm or less, as calculated from a sum of absorbance of peaks thereof in an HPLC analysis under specific conditions after specific sample preparation.

The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w). The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative. Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w). The purified monoterpene can be used to treat a disease such as cancer. The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents.

The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w). The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative. Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w). The purified monoterpene can be used to treat a disease such as cancer. The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents.

A recycle content propanol and method of making a recycle content propanol wherein the recycle content is derived directly or indirectly from the cracking of recycle content pyrolysis oil and/or gas. The cracking of the pyrolysis oil can be conducted in a gas furnace or a split furnace.